Glycoprotein IIb/IIIa inhibitors in acute coronary syndromes

Cleve Clin J Med. 2000 Feb;67(2):131-40. doi: 10.3949/ccjm.67.2.131.

Abstract

Glycoprotein (GP) IIb/IIIa inhibitors are potent antiplatelet agents and represent an exciting breakthrough in the treatment of acute coronary syndromes. However, their safety and cost-effectiveness require further investigation, and more information on risk stratification is needed to clarify which patients benefit the most from empiric use of these agents.

Publication types

  • Review

MeSH terms

  • Abciximab
  • Angina, Unstable / drug therapy*
  • Antibodies, Monoclonal / therapeutic use
  • Drug Therapy, Combination
  • Eptifibatide
  • Fibrinolytic Agents / administration & dosage
  • Fibrinolytic Agents / therapeutic use*
  • Heparin / therapeutic use
  • Humans
  • Immunoglobulin Fab Fragments / therapeutic use
  • Myocardial Infarction / drug therapy*
  • Peptides / therapeutic use
  • Platelet Aggregation Inhibitors / administration & dosage
  • Platelet Aggregation Inhibitors / therapeutic use*
  • Platelet Glycoprotein GPIIb-IIIa Complex / antagonists & inhibitors*
  • Tirofiban
  • Tyrosine / analogs & derivatives
  • Tyrosine / therapeutic use

Substances

  • Antibodies, Monoclonal
  • Fibrinolytic Agents
  • Immunoglobulin Fab Fragments
  • Peptides
  • Platelet Aggregation Inhibitors
  • Platelet Glycoprotein GPIIb-IIIa Complex
  • Tyrosine
  • Heparin
  • Tirofiban
  • Eptifibatide
  • Abciximab